Key clinical point: Interleukin-27 was able to decrease cytotoxic effects of bone marrow natural killer cells in CLL.
Major finding: BM-NK cell cytotoxicity was significantly increased in cells treated with interleukin 27 (P < .001).
Study details: Bone marrow aspirates and peripheral blood samples were obtained from 12 untreated CLL patients and tested in vitro.
Disclosures: The research was supported by Semnan (Iran) University of Medical Sciences. The authors reported that they had no conflicts of interest.
Hemati M et al. Int Immunopharmacol. 2020;82:doi.org/10.1016/j.intimp.2020.106350.